BioSpace News Archive

Boston Scientific Corporation (NYSE: BSX) will participate in TD Cowen’s 44th Annual Health Care Conference on Wednesday, March 6, 2024.

Sanofi launches ‘Cancer & Work: Acting Together’, a global program to support Sanofi employees whose lives are impacted by cancer and other critical illnesses.

Palatin Technologies, Inc. today announced database lock for its PL9643 MELODY-1 pivotal Phase 3 clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED).

QurAlis Corporation today announced that Kasper Roet, Ph.D., CEO and co-founder, will present a corporate overview at the following investor conferences in February.

iRegene Therapeutics Co., Ltd (iRegene) recently announced that NouvNeu001, the company’s first innovative product, has completed the dosing for its first patient at Beijing Hospital, and the patient has also successfully concluded the observation period.

Guangzhou Fermion Technology Co., Ltd. (Fermion) is pleased to announce the approval of the Investigational New Drug (IND) for its TYK2 JH2 inhibitor, FZ007-119, by the China National Medical Products Administration (NMPA).

Johnson & Johnson today announced topline results from the pivotal Phase 3 VIVACITY study of nipocalimab in adults living with generalized myasthenia gravis (gMG) as well as the Phase 2 DAHLIAS study of nipocalimab in adults with Sjögren’s disease (SjD).

AnaMar, a clinical-stage biotech company developing first-in-class anti-fibrotic 5-HT2B receptor antagonists, announces that the European Medicines Agency and the United States Food and Drug Administration have granted orphan drug designation to its lead clinical candidate, AM1476 for the treatment of systemic sclerosis.

Danaher Corporation, a global science and technology innovator, launched a strategic collaboration with Cincinnati Children’s Hospital Medical Center, with the goal of improving patient safety by addressing a leading cause of failure in clinical trials.

Adverum Biotechnologies, Inc. today announced that it has agreed to sell approximately 106.25 million shares of its common stock (or pre-funded warrants in lieu thereof) to a select group of institutional and accredited healthcare specialist investors in a private placement, at a price per share of $1.20, representing a premium of approximately 20% to Adverum’s 30-day volume-weighted average price.